Targeting of the NLRP3 Inflammasome for early COVID-19
C. Marchetti, K. Mould, I. W. Tengesdal, W. J. Janssen, C. A. Dinarello
This study identifies early NLRP3 inflammasome activation in COVID-19 patients, linking it to cytokine release syndrome and suggesting NLRP3 as a therapeutic target.
bioRxiv · Feb 24, 2021 · PreprintImmunology